- Investing Ideas
- Australian Pharmaceuticals & Biotech High Return On Equity, Low Debt
Australian Pharmaceuticals & Biotech High Return On Equity, Low Debt
Results
2
0 new
Stocks with a return on equity of over 30% and a debt to equity ratio below 1.
2 companies
Bioxyne
Market Cap: AU$211.2m
Manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czechia, Switzerland, France, Germany, and Japan.
BXN
AU$0.093
7D
1.1%
1Y
200.0%
Cann Group
Market Cap: AU$6.5m
Engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe.
CAN
AU$0.004
7D
0%
1Y
-66.7%